GlassScriptPhysician profile
Oleg E Akilov
NPI 1316274590
$408,803.00
in general payments reported to CMS, 2019-2025
27 companies · $161K in 2025
The $161K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $8,327 · 2021: $723 · 2022: $95K · 2023: $56K · 2024: $87K · 2025: $161K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $229K · Travel and Lodging: $28K · Consulting Fee: $20K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Food and Beverage: $9,500 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $229,315.00 |
| Travel and Lodging | $28,051.23 |
| Consulting Fee | $20,189.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,250.00 |
| Food and Beverage | $9,499.82 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $251,149.05 | 2019-2025 | Poteligeo |
| Therakos LLC | $92,308.48 | 2025 | Cellex, Uvadex |
| Helsinn Therapeutics (U.S.), INC. | $32,456.14 | 2019-2025 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19,716.42 | 2023-2025 | Targretin, Siliq, Cabtreo |
| Helsinn Healthcare Sa | $5,796.49 | 2025 | Valchlor |
| Mallinckrodt Hospital Products INC. | $2,439.08 | 2021-2024 | Cellex, Uvadex |
| Dr.Reddy'S Laboratories,INC. | $1,500.00 | 2020 | |
| Abbvie INC. | $707.86 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $500.00 | 2020 | |
| Innate Pharma, INC | $483.33 | 2021 | |
| Janssen Biotech, INC. | $352.04 | 2020-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $217.37 | 2023-2024 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $213.24 | 2022-2025 | Libtayo, Dupixent |
| Organon LLC | $204.88 | 2025 | Vtama |
| Ucb, INC. | $160.01 | 2025 | Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $146.34 | 2024 | Zoryve |
| Amgen INC. | $114.56 | 2025 | Otezla |
| Secura Bio, INC. | $87.75 | 2025 | Copiktra |
| Bausch Health US, LLC | $66.56 | 2024 | Siliq, Targretin |
| Genzyme Corporation | $65.32 | 2025 | |
| Novartis Pharmaceuticals Corporation | $61.52 | 2025 | |
| Krystal Biotech INC | $29.49 | 2023 | Vyjuvek |
| Seagen INC. | $27.07 | 2019-2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleg Akilov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.